you are viewing a single comment's thread.
I was expecting it to go up, even today. It's a steal here at <$100M market cap. Treximet alone is worth that (6 years x $16M/YR). It does make sense for GSK to snatch it up here. Make an offer at $6, they would basically get Vimovo royalties and PA for $30M.